Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India.

Autor: Yadav A; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Goyal P; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Agrawal CR; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Bothra SJ; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Jain P; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Choudhury KD; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Gupta SK; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Sharma M; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Bajaj R; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Upadhyay A; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Dash P; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Doval DC; Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Jazyk: angličtina
Zdroj: Indian journal of cancer [Indian J Cancer] 2020 Jan-Mar; Vol. 57 (1), pp. 76-83.
DOI: 10.4103/ijc.IJC_469_18
Abstrakt: Introduction: Squamous cell carcinoma of head and neck (SCCHN) account for approximately 30-33% of all cancer and the median survival for recurrent and metastatic(R/M) SCCHN remains less than 1 year despite modern advances in therapy. Chemotherapy, usually single agent remains the backbone of therapy in these patients. EGFR antibodies are being used in (R/M) SCCHN. Nimotuzumab is one such agent that has anti-EGFR action similar to other agents without similar skin toxicity.
Methods: Prospective, interventional, non-randomized study done at Rajiv Gandhi Cancer Institute and Research Centre. A total 124 patients were enrolled and divided into Arm A (Chemotherapy + Nimotuzumab) and Arm B (Chemotherapy) in a ratio of 1:1 i.e., 62 in each arm. They were evaluated and treated as per protocol after a written informed consent. Statistical analysis was done using the SPSS software. Quantitative variables were compared using Unpaired t-test/Mann-Whitney Test. Qualitative variables were compared using Chi-Square test /Fisher's exact test. Kaplan-Meier analysis was used to assess the PFS, with log rank test for comparison between the groups. A p value of < 0.05 was considered statistically significant.
Results: The most frequent primary location of tumor was oral cavity (n=38, 69%) and (n=33, 56.9%) in both arms. The overall response rate in Arm A was 38.2% and 19% in Arm B (p= 0.023). The disease control rate in Arm A was 74.5% and 43.1% Arm B (p= 0.0007). The median PFS in Arm A was 5.2 months whereas it was 3.2 months in Arm B (p= 0.009).
Conclusion: In this study, the combination of Nimotuzumab plus platinum/taxane based chemotherapy was active and well tolerated in Indian patients in R/M SCCHN. Addition of Nimotuzumab to chemotherapy had a response rate of 38.2% and median PFS of 5.2 months are strong arguments for clinically testing this combination.
Competing Interests: None
Databáze: MEDLINE
Externí odkaz: